Vials of DAXXIFY (Photo: Business Wire) NASHVILLE, Tenn. - The U.S. Food and Drug Administration approved an injection designed to minimize the appearance of facial wrinkles, creating more competition in a market that has long been dominated by Botox.
The anti-wrinkle injection, called Daxxify, was developed by manufacturer Revance Therapeutics, which announced the approval on Thursday.
Studies showed the drug can temporarily improve "moderate to severe frown lines" in adults for a median duration of six months, which is up to two months longer than the period generally provided by Botox.Botox received initial U.S.
approval for therapeutic use in 1989 and was later studied and rebranded for the treatment of moderate to severe frown lines.